PubMed · 1980 · 18 citations · 14 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPreventive CardiologyCholesterol MetabolismDyslipidemia ManagementDyslipidemia PharmacotherapyFamilial HypercholesterolemiaLipid ManagementLipid-lowering TherapyCholesterol-lowering EffectsDouble-blind TrialsHigh-density Lipoprotein Cholesterol ManagementHyperlipidemia TreatmentLow-density Lipoprotein Cholesterol LoweringLow-density Lipoprotein Cholesterol ReductionPlasma Cholesterol Levels
Probucol (1 g per day) was administered in a double-blind crossover trial to 16 patients with familial hypercholesterolemia who had previously been tested for their response to clofibrate. Probucol led to a fall in the plasma cholesterol concentration of 15% or more (mean 20.2%) in 5 of the 12 clofibrate-resistant patients and between 8% and 15% in 3 others. The reduction was statistically significant in 7 of these 12 patients as well as in 3 of the 4 patients sensitive to clofibrate. Thus, probucol has a place in the treatment of patients with primary hypercholesterolemia who do not respond to clofibrate.
14
Quantitation of apolipoprotein A-I of human plasma high density lipoprotein
John J. Albers, Patricia Wahl, Veneracion G. Cabana et al. · Metabolism · 1976 · 345 citations
Clofibrate in Coronary Heart Disease
L. R. Krasno · JAMA · 1972 · 95 citations